Cost of Hospital Admissions in Medicare Patients With Atrial Fibrillation Taking Warfarin, Dabigatran, or Rivaroxaban.
作者信息
Vaughan Sarrazin Mary S, Jones Michael, Mazur Alexander, Cram Peter, Ayyagari Padmaja, Chrischilles Elizabeth
出版信息
J Am Coll Cardiol. 2017 Jan 24;69(3):360-362. doi: 10.1016/j.jacc.2016.11.023.
Abstract
摘要
相似文献
1
Cost of Hospital Admissions in Medicare Patients With Atrial Fibrillation Taking Warfarin, Dabigatran, or Rivaroxaban.服用华法林、达比加群或利伐沙班的医疗保险房颤患者的住院费用。
J Am Coll Cardiol. 2017 Jan 24;69(3):360-362. doi: 10.1016/j.jacc.2016.11.023.
2
Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.比较 CMS 医疗保险人群中老年非瓣膜性心房颤动患者使用直接口服抗凝剂与华法林的临床结局。
J Thromb Thrombolysis. 2019 Aug;48(2):240-249. doi: 10.1007/s11239-019-01838-5.
3
Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study.非华法林口服抗凝剂共付额与房颤患者的依从性：一项基于人群的队列研究。
Am Heart J. 2021 Mar;233:109-121. doi: 10.1016/j.ahj.2020.12.010. Epub 2021 Jan 14.
4
Factors influencing dabigatran or warfarin medication persistence in patients with nonvalvular atrial fibrillation.影响非瓣膜性心房颤动患者达比加群或华法林药物治疗持续性的因素。
J Comp Eff Res. 2018 Jul;7(7):685-691. doi: 10.2217/cer-2017-0081. Epub 2018 May 29.
5
Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.伴有单一卒中危险因素的房颤患者中标准剂量非维生素 K 拮抗剂口服抗凝剂和华法林的有效性和安全性：一项全国性队列研究。
JAMA Cardiol. 2017 Aug 1;2(8):872-881. doi: 10.1001/jamacardio.2017.1883.
6
Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin.新诊断的非瓣膜性心房颤动患者中，达比加群、利伐沙班或华法林新治疗患者的卒中及出血相关医疗资源利用和成本比较。
Expert Rev Pharmacoecon Outcomes Res. 2019 Apr;19(2):203-212. doi: 10.1080/14737167.2019.1527220. Epub 2018 Oct 4.
7
[Not Available].[不可用]。
Lakartidningen. 2018 Dec 4;115:FAXZ.
8
Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.新型口服抗凝药用于非瓣膜性心房颤动患者卒中预防的成本效益分析
Curr Cardiol Rep. 2015 Aug;17(8):61. doi: 10.1007/s11886-015-0618-4.
9
Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.英国背景下新型口服抗凝剂预防心房颤动患者中风和全身性栓塞的成本效益比较。
Clin Ther. 2014 Dec 1;36(12):2015-2028.e2. doi: 10.1016/j.clinthera.2014.09.015. Epub 2014 Oct 23.
10
Direct Oral Anticoagulants in Cardiac Amyloidosis-Associated Heart Failure and Atrial Fibrillation.直接口服抗凝剂在心脏淀粉样变性相关心力衰竭和心房颤动中的应用
Am J Cardiol. 2022 Feb 1;164:141-143. doi: 10.1016/j.amjcard.2021.10.018. Epub 2021 Nov 27.
引用本文的文献
1
The role of personalized atrial modeling in understanding atrial fibrillation mechanisms and improving treatment.个体化心房建模在理解心房颤动机制和改善治疗中的作用。
Int J Cardiol. 2019 Jul 15;287:139-147. doi: 10.1016/j.ijcard.2019.01.096. Epub 2019 Jan 31.
2
Better clinical outcome with direct oral anticoagulants in hospitalized heart failure patients with atrial fibrillation.直接口服抗凝剂用于合并心房颤动的住院心力衰竭患者可带来更好的临床结局。
BMC Cardiovasc Disord. 2018 Jan 25;18(1):11. doi: 10.1186/s12872-018-0746-z.
本文引用的文献
1
Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data.2010 - 2011年医疗保险数据中达比加群的出血风险
JAMA Intern Med. 2015 Jul;175(7):1245-7. doi: 10.1001/jamainternmed.2015.1299.
2
Matching by propensity score in cohort studies with three treatment groups.倾向评分匹配在三处理组队列研究中的应用。
Epidemiology. 2013 May;24(3):401-9. doi: 10.1097/EDE.0b013e318289dedf.
3
Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry.与心房颤动复发相关的医疗资源利用和成本：FRACTAL注册研究
J Cardiovasc Electrophysiol. 2007 Jun;18(6):628-33. doi: 10.1111/j.1540-8167.2007.00819.x. Epub 2007 Apr 19.
4
Comparisons of two-part models with competitors.两部分模型与竞争对手的比较。
Stat Med. 2001 Apr 30;20(8):1215-34. doi: 10.1002/sim.790.
Zotero 插件